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Abstract: 
 
Magnetic nanoparticles that display high saturation magnetization and high 
magnetic susceptibility with a size less than 200 nm are of great interest for 
medical applications. Investigations of magnetic nanoparticles have been 
increasing over the last decade.  Magnetite nanoparticles are particularly 
desirable since the biocompatibility of these particles has already been 
proven. Several synthetic and natural polymers have been employed to 
stabilize magnetite nanoparticles and enhance their function in vivo. The goal 
of this work has been to develop a unique methodology for synthesizing 
magnetite within polymer nanoparticle dispersions so that the resultant 
magnetite-polymer particles may be used in a range of biomedical 
applications, specifically as an MRI contrast agent. A method was developed 
for preparing ≈150 nm polyvinylamine (PVAm) nanoparticles containing iron 
oxide. These polymeric nanoparticles offer colloidal stability and reactive 
primary amines for drug conjugation or surface modification.   
 The polymer-magnetite nanoparticles described in this thesis exhibited 
a maximum of 12% wt. magnetite and a saturation magnetization of ~30 
emu/mg. Transmission electron microscopy (TEM) images showed that the 
dispersions contained ≈100 to 150 nm diameter PVAm nanoparticles 
incorporated with iron oxide particles with a size less than ≈10 nm. The ability 
to synthesize iron oxide inside functionalized polymeric nanoparticles offers 
iv 
an effective approach to prevent nanoparticle agglomeration and the potential 
to enable ligand grafting. Stabilized magnetic PVAm nanoparticles may 
provide a unique synthetic approach to enhance MRI contrast and may offer a 
platform for molecular imaging. 
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Fundamentals of Magnetic Nanoparticles 
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Introduction: 
Magnetic nanoparticles have been intensively studied for their applications in 
biomedical areas such as enzyme and protein immobilization, targeted drug 
delivery, magnetically controlled transport of anticancer drugs, in vitro cell 
separations and magnetic resonance (MR) contrast enhancement [1-7]. Several 
investigations have been carried out in the field of superparamagnetic iron oxide 
nanoparticles since biocompatibility of these particles has already been proven 
[8]. In MR imaging, superparamagnetic nanoparticles are especially desirable as 
they may potentially provide higher contrast enhancement than conventional 
paramagnetic Gd-based contrast agents [9-12].  
 The direct use of these particles in vivo, however, can result in formation 
of agglomerates in the blood plasma potentially increasing clearance by 
macrophages and the risk of occusions [13, 14]. Furthermore, aggregation of iron 
oxide nanoparticles reduces the superparamagnetic properties [15].  
Agglomeration results because the surface energy of iron oxide nanoparticles is 
greatly increased as the ratio of surface area to volume increases [1]. To 
overcome this difficulty and to use these particles for biomedical purposes, it is 
essential to engineer the surface of the nanoparticles with substances that make 
them stable, biodegradable and non-toxic in physiological conditions. In addition, 
conjugation or inclusion of complex biological molecules, such as peptides, 
hormones, vitamins or drugs is desired [16-19].  
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 When considering coating materials for biomedical applications, it is 
usually required that particles should have a hydrophilic surface and a final size 
less than 200 nm to ensure extended circulation time in the blood and minimized 
clearance by macrophages. In addition, a particle sizes more than ≈10 nm is 
necessary to escape the renal clearance. Several methods have been reported 
for surface modification of superparamagnetic iron oxide nanoparticles. These 
methods are reviewed briefly. The alternative synthesis approach reported here 
included: (1) designing polymeric nanoparticles with hydrophilic characterization 
and amine functional groups as a metal chelating agent; (2) carrying out the 
oxidation reaction inside the polymeric network; (3) tailoring the iron 
concentration inside the polymeric nanoparticles to successfully maintain the 
stochiometry of the reaction; and (4) fabricating stable magnetic PVAm 
nanoparticles with narrow size distribution. 
  In chapter one, a review of magnetic nanoparticle synthesis and 
characterization methods are discussed. This chapter focuses on iron oxide 
nanoparticles that display superparamagnetism, the benefits of 
superparamagnetic iron oxide nanoparticles, conventional and current 
stabilization techniques, and benefits of superparamagnetic nanoparticles as MRI 
contrast agents. It also includes the fundamentals of magnetism and biomedical 
application of magnetic nanoparticles. In chapter two, a novel research approach 
to fabricate stabilized superparamagnetic nanoparticles is reported. Magnetic 
polyvinylamine nanoparticles with a narrow size distribution were prepared by 
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carrying out the oxidation reaction to produce magnetite inside PVAm 
nanoparticles. PVAm is a water soluble polymer with a relatively high density of 
reactive amino groups [20] inside and at the surface of polymer nanoparticles, 
which have been utilized as a chelating agent for heavy metals due to the 
presence of primary amines [21]. This property was leveraged to coordinate iron 
ions within PVAm nanoparticles. The iron was then oxidized in situ to produce 
magnetic PVAm nanoparticles. 
 
1. Fundamentals of Magnetic Nanoparticles Synthesis and Characterization 
 
1.1. Magnetism 
The magnetic properties of ferromagnetic materials are the result of their aligned 
unpaired electron spins. These materials retain magnetization even after the 
removal of an external field. The term superparamagnetic refers to single domain 
particles that reach magnetization equilibrium at experimental temperature in a 
relatively short time. The atomic magnetic dipoles of paramagnetic materials 
have a tendency to align with an external magnetic field. These particles have a 
small, positive magnetic susceptibility (i.e., ability to strengthen the field they are 
in), and return to their random orientation in the absence of a magnetic field due 
to Brownian fluctuations. In contrast, superparamagnetic iron oxide nanoparticles 
are known to have much larger susceptibilities compared with paramagnetic 
materials because the entire crystal aligns with the applied field due to their 
single crystal nature. Their moments align in the direction of magnetic filed when 
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placed in an external field and enhance the magnetic flux and they retain no 
magnetization after removal of the external field (Fig. 1).  
 
Figure 1. Magnetic moments of magnetic materials in the presence of an applied magnetic field. 
 
1.2. Synthesis of Magnetic Nanoparticles 
There are several methods that are generally used to produce magnetic iron 
oxide nanoparticles. However, the two fundamental approaches currently being 
used to synthesize magnetite nanoparticles are aqueous co-precipitation and 
microemulsion. 
 
     1.2.1. Synthesis of Iron Oxide Nanoparticles via Aqueous co-precipitation 
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Conventionally, magnetite is prepared by adding a base to an aqueous mixture of 
Fe2+ and Fe3+ chloride at a 1:2 molar ratio. The precipitated magnetite is black in 
color. Figure 2 shows the chemical reaction of iron ions in the presence of a 
strong base. The overall reaction is [8, 22]: 
 
 Fe2++ 2Fe3++ 8OH-            Fe3O4 + 4H2O                        (1)  
 
A complete precipitation of Fe3O4 is expected between pH 9 and 14, while 
maintaining a 2:1 molar ratio of Fe3+:Fe2+ under an oxygen free environment. If 
the oxygen free environment is not maintained, Fe3O4 might be further oxidized 
as  
 
Fe3O4 + 0.25 O2 + 4.5 H2O             3Fe(OH)3                    (2)  
 
This would critically affect the physical and chemical properties of the magnetic 
particles. In order to prevent them from possible oxidation in the air as well as 
from agglomeration, Fe3O4 nanoparticles produced by reaction 1 are usually 
protected by adding organic or inorganic molecules (e.g. surfactants) as a 
coating agent during the precipitation process. Since the reaction kinetics are 
strongly related to the oxidation speed of iron species, the synthesis of particles 
must be done in an oxygen-free environment (e.g. N2). Bubbling nitrogen gas 
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through the solution not only protects oxidation of the magnetite but also reduces 
the particle size when compared to methods that do not remove oxygen [23-25]. 
 Advances in the use of magnetic nanoparticles in biomedical applications 
depend on the synthetic method, size, size distribution, magnetic properties and 
the particles’ surface characteristics. 
 
 
 
 
 
 
 
 
 Figure 2. Reaction mechanism of iron oxide formation from an aqueous mixture of ferrous and 
ferric chloride salts in the presence of a strong base. 
 
Stable aqueous suspensions can be fabricated using various saturated and 
unsaturated fatty acids as primary and secondary surfactants [26]. In practice, 
however, little control is actually gained over the size and size distribution of the 
nanoparticles and, moreover, because of the low concentration of reagent, only 
small quantities of iron oxide can be obtained.   
 
   1.2.2. Synthesis of Iron Oxide Nanoparticles via Microemulsion 
 
Fe (OH)x3-x 
+ 
Fe (OH)v2-y 
 
Magnetite 
 
Fe3O4 
Deprotonation 
Fe3+ + H2O    Fe (OH)x3-x 
 
Deprotonation 
Fe2+ + H2O    Fe (OH)y2-y 
 
Oxidation
Dehydration 
pH ~ 9, 60°C 
 10 
A microemulsion is defined as a stable dispersion of two immiscible fluids plus an 
emulsifier (Fig 3) [27]. This method has recently been used to synthesize 
superparamagnetic iron oxide nanoparticles. The advantage of this method over 
previous methods is the control over size and shape of nanoparticles. In oil-in-
water microemulsions, nanoparticles are synthesized by suspending a ferrous 
salt-surfactant precipitate in an aqueous solution. A base is then added to form a 
magnetic precipitate [28]. In water-in-oil microemulsions, the aqueous phase is 
dispersed as microdroplets surrounded by a monolayer of surfactant molecules 
in the continuous inorganic phase [29]. A soluble metal salt is included in the 
aqueous phase of the microemulsion. A strong base is then added to form the 
iron oxide precipitate. The superparamagnetic iron oxide nanoparticles are 
precipitated and oxidized within the nanosized micelle.  
 The water-in-oil approach is a more common microemulsion synthesis 
technique for nanoparticles with biomedical applicability. Research shows that 
this approach results in fairly uniform populations of magnetic nanoparticles [1]. 
Depending on the solvent in which nanoparticles will be used, an appropriate 
surfactant can be applied to prevent agglomeration [30]. It should be noted that 
the homogeneous size of nanoparticles resulting from the microemulsion method 
is highly dependent on the approach. Poor crystallinity of superparamagnetic 
nanoparticles fabricated in microemulsions is reported as a disadvantage of this 
method since it usually reduces the instinct superparamagnetic behavior of 
nanoparticles [31]. 
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Figure 3. Scheme of a microemulsion reaction in the presence of an emulsifier. 
 
 
1.3. Stabilization of Iron Oxide Nanoparticles 
The stability of the iron oxide nanoparticles in solution is of utmost importance in 
the preparation and storage process. Magnetic iron oxide particles have 
hydrophobic surfaces and the ratio of their surface area to volume is relatively 
high. Due to hydrophobic interactions between the particles, agglomeration can 
occur resulting in increased particle size. These agglomerates, then, exhibit 
strong magnetic dipole–dipole attractions between the agglomerated particles 
and show ferromagnetic behavior [32]. Ferromagnetism is defined as the 
phenomenon by which materials in an external magnetic field become 
magnetized and remain magnetized for a period after the material is no longer in 
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the field. When two large-particle clusters approach one another, both of them 
come into the magnetic field of the neighbor. Besides the induction of attractive 
forces between the particles, each particle is in the magnetic field of its neighbor 
and gets further magnetized [33]. These magnetic particles then adhere, further 
resulting in a mutual magnetization and propagating agglomeration.  
 Surface modification of magnetic nanoparticles is often necessary to 
mitigate magnetic interaction. To prevent the agglomeration of these 
nanoparticles and enable biomedical applications, it is essential to engineer the 
surface of the nanoparticles with substances that make them stable in 
physiological conditions and make them able to conjugate to complex biological 
molecules [19]. When considering the coating materials, such as polymer or 
surfactant, for biomedical application, it is usually required that particles should 
have a hydrophilic, biodegradable and non-toxic surface.  To prevent 
agglomeration of the nanoscale particulate, the coating layer is usually added at 
the time of preparation. Most of these polymers adhere to surfaces of magnetic 
nanoparticles. However, to enable these nanoparticles for biomedical 
applications one should be careful regarding polymer selection as a coating 
layer. The protecting layer desired for biomedical applications are non-toxic, 
hydrophilic and biodegradable.  
 
1.3.1. Different Coating Layers to Stabilize Iron Oxide Nanoparticles 
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Several synthetic and natural polymers have been reported to modify the surface 
of superparamagnetic nanoparticles to enhance their function in vivo. 
Poly(ethylene-co-vinylacetate), poly(vinylpyrrolidone) (PVP), poly(lactic-co-
glycolic acid) (PLGA), poly(ethyleneglycol) (PEG), poly(vinyl alcohol) (PVA), etc. 
are typical examples of synthetic polymeric systems [1, 34, 35]. Natural polymer 
systems include use of gelatin, dextran, chitosan, pullulan, etc. Various 
surfactants, such as sodium oleate and dodecylamine are also usually used to 
enhance dispersibility of magnetite nanoparticles in an aqueous medium. Use of 
these materials often resulted in the formation of iron oxide nanoparticles with a 
wide particle size distribution and poor crystallinity [34]. Table 1 provides a list of 
materials that have been used as a stabilizer for magnetic nanoparticles with 
biomedical applications. 
Table 1. Different polymer that can be used to stabilize iron oxide nanoparticles. 
 
Polymers/molecules                Advantages                                           References 
 
Polyethylene glycol (PEG) Non-covalent immobilization of PEG                     [1]                    
on the surface improves the biocompatibility, 
blood circulation time and internalization     
efficiency of the nanoparticles 
Dextran   Enhances the blood circulation time, stabilizes    [36]    
the colloidal solution 
Polyvinylpyrrolidone (PVP) Enhances the blood circulation time, stabilizes    [37]             
the colloidal solution 
Polyvinyl alcohol (PVA) Prevents coagulation of particles, giving rise to    [38]    
monodisperse particles 
Polypeptides Good for cell biology, e.g. targeting to cells          [39]      
Chitosan A semi-synthesized cationic linear polymer that   [40] 
                                           is widely used as a non-viral gene delivery system;  
biocompatible, hydrophilic, used in agriculture,  
food, medicine, biotechnology, textiles, polymers, 
and water treatment 
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   1.3.1.1. Surface Modification of Iron Oxide Nanoparticles with Polymer 
Stabilizers 
 
Stabilization of iron oxide nanoparticles usually takes place during the 
precipitation of magnetic nanoparticles. This usually prevents agglomeration of 
nanoparticles and results in monodisperse particle size distributions [36, 40]. A 
variety of approaches have been reported in the field of iron oxide stabilization. 
Ugelstad et al. has reported direct precipitation of iron salts inside the pores of 
microporous polystyrene seeds [41]. The particles obtained had a large size of 
2.8-4.5 mm and showed good magnetic properties. In another study, Sauzedde 
et al. have reported the fabrication of hydrophilic, temperature-sensitive latex 
magnetic nanoparticles by encapsulating adsorbed iron oxide nanoparticles in an 
oppositely charged polystyrene-core/poly (N-isopropylacrylamide) shell [42]. In 
another study, Chatterjee et al. have  reported the fabrication of cross-linked 
albumin magnetic microspheres [43]. Lee et al. have modified the surface of 
magnetic nanoparticles with PVA by precipitation of iron salts in PVA aqueous 
solution to form a stable dispersion [44]. They found that the crystallinity of the 
particles decreased with increasing PVA concentration, while the morphology 
and particle size remained almost unchanged. Another methodology to stabilize 
magnetic nanoparticles is through self-assembly of ligand-stabilized 
nanoparticles into two- and three-dimensionally ordered arrays [45]. Results from 
this research demonstrated that self-assembly of ligand-stabilized nanoparticles 
is mainly driven by the interactions of the organic ligands rather than by the 
interaction of the magnetite cores.  
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 To improve dispersibility, magnetite particles are often modified after 
precipitation [46]. Gupta et al. have shown that the synthesis of magnetic 
polymeric nanoparticles with a magnetite core and a polymeric shell is possible 
using an inverse microemulsion polymerization process [29]. This strategy is 
based on utilizing the inverse microemulsion approach to modulate the surface of 
magnetic nanoparticles with PEG. Their results demonstrated that the inverse 
microemulsion is a better method compared with other bulk precipitation methods 
to synthesize magnetic polymeric nanoparticles since it offers improved control 
over iron oxide amount and magnetic properties. Among synthetic polymers, 
PEG is known to improve the biocompatibility and the blood circulation of 
magnetic nanoparticles [47]. However, in some cases a poor chemical stability of 
PEG-modified magnetic nanoparticles has been reported. 
 
1.3.2. Surface Modification with Non-Polymeric Organic Stabilizers 
(Surfactant) 
 
Because use of polymers  can lead to substantial thickness, surface protection 
using the non-polymeric organic layer, like oleic acid or small monomeric organic 
molecules,  has also been developed as a method to stabilize magnetic 
nanoparticles [48]. Sahoo et al. have reported the surface protection of magnetite 
in organic solvent by oleic acid, lauric acid, dodecylphosphonic acid, 
hexadecylphosphonic acid, and dihexadecylphosphonic acid [49]. They found 
that alkyl phosphonates and phosphates could be used for obtaining 
thermodynamically stable dispersions of magnetic nanoparticles. Oleic acid and 
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stearic acid are similar surfactants which, lead to stability and to precipitation of 
ferrofluid suspensions respectively. Portet et al. have developed monomeric 
organic molecules as coating materials to avoid a thick polymeric layer on the 
surface [30]. These small molecules produce a homogeneous coating on the 
entire iron oxide core and inhibit protein absorption. 
  
1.4. Characterization of magnetic nanoparticles 
Crystal structure and magnetic properties of stabilized magnetic nanoparticles 
are usually tested to predict their ability to enhance MRI contrast in vivo. X-Ray 
Diffraction (XRD) and superconductive quantum interference devices (SQUID) 
are usually applied to study the crystallinity and magnetization of particles 
respectively. These methods are introduced briefly below. 
 
1.4.1. X-Ray Diffraction (XRD) 
XRD is a technique used to characterize the crystal structure in polycrystalline or 
powdered solid samples. Powder diffraction is a type of XRD commonly used to 
identify unknown substances, by comparing diffraction data against a database 
maintained by the International Centre for Diffraction Data. These techniques are 
based on observing the scattered intensity of an x-ray beam hitting a sample as a 
function of incident and scattered angle, polarization, and wavelength or energy. 
The peak intensity in XRD result can be used to quantify the proportion of iron 
oxide forms in a mixture by comparing experimental peak and a reference peak 
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intensity. The crystal size also can be calculated from line broadening from the 
XRD pattern using the Scherrer equation. 
 
1.4.2. Superconducting Quantum Interference Devices (SQUID) 
The magnetization properties usually are investigated using Superconducting 
Quantum Interference Device. This device provides fundamental magnetic 
behavior quantification including saturation magnetization (MS), magnetic 
remanence (MR), and particle size information. Several other characterization 
methods are also available to investigate the properties of magnetic particle 
systems. These methods include vibrating sample magnetometer (VSM) which 
provides fundamentals magnetic behavior quantification, thermal gravimetric 
analysis (TGA), and Mössbauer spectrometry. TGA and Mössbauer spectrometry 
also provide the dispersion quality, particle size and magnetic relaxation times 
and core/surface magnetic property variations for particles respectively. 
 
1.5. Biomedical application of magnetic nanoparticles 
Superparamagnetic nanoparticles have a high potential for several biomedical 
applications based on their physical and chemical properties. They are a 
potential candidate to be used in (a) drug delivery, (b) tissue repair, (d) 
detoxification of biological fluids, (e) hyperthermia (f) magnetic resonance 
imaging (MRI) [1-7]. The particles must show a high magnetic saturation, 
biocompatibility and a functional surface in order to be considered a good 
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candidate for above applications. The surfaces of these particles could be 
modified through organic or non-organic molecules [50]. It is also been reported 
that the surface of magnetic nanoparticles have been modified through oxide 
layers (e.g. silica or alumina) in some cases [50]. These modifications are 
suitable to further be functionalized by the attachment of various bioactive 
molecules such as peptides, antibodies, drugs, etc. As the magnetic particles 
accumulate to the site of action, they can play an important role in functional 
validation through MRI by enhancing the magnetic flux at that site to locate and 
measure the targeting ability of a drug carrier. In all cases, superparamagnetic 
particles are of interest because they do not retain any magnetism after removal 
of the magnetic field [51]. The effectiveness of the particles as MRI contrast 
agents depends upon (a) high magnetic susceptibility in order to have an 
effective magnetic enrichment, [52] (b) size and size distribution of particles, (c) 
superparamagnetic behavior, and (d) ability of the surface to further be modified 
for specific biomedical applications [47]. Varanda et al. have reported a linear 
correlation between saturation magnetization and particle size, suggesting that 
shape and surface curvature of nanoparticles can have an effect on magnetic 
properties [53]. Studies show that following systemic administration, larger 
particles with diameters greater than 200 nm are usually taken up by 
macrophages resulting in decreased blood circulation time; and particles with 
diameters of less than 10 nm are rapidly removed through renal clearance. This 
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suggests particles ranging from 10 to 200 nm are desirable for intravenous 
injection since they have the most prolonged blood circulation times [54]. 
 
1.5.1. Drug delivery 
Another promising application of magnetic nanoparticles is in drug delivery [1]. 
Surface modified magnetic nanoparticles can be employed as a drug carrier for 
site-specific delivery of drugs (Fig 4). As the magnetic particles traverse the 
target organ capillaries, an applied external magnetic field may retain these 
particles at the desired site. Retained particles may undergo extravasation, which 
could ultimately lead to intracellular (i.e., tumor cell) drug uptake. Several studies 
demonstrated that biodegradable polymers are ideal candidates for drug carriers 
since they show minimum toxicity and immunological response [55, 56] . The 
potential advantage of a magnetically guided drug delivery system is reduced 
drug doses and potential side effects to healthy tissues. It has also been reported 
that PEG-coated superparamagnetic nanoparticles did not affect cell adhesion 
behavior or morphology after incubation with immortalized fibroblasts [1]. Particle 
size and charge along with surface must be modified to enhance their blood 
circulation time as well as bioavailability of the particles within the body [57]. In 
addition, magnetic properties and cellular internalization of particles strongly 
depends on the size and size distribution of the magnetic nanoparticles [58]. 
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Fig 3. Magnetic nanoparticles as drug carrier vehicles. 
 Superparamagnetic iron oxide nanoparticles of narrow size range are 
easily produced and stabilized with various polymeric and non-polymeric coating 
since they are likely to be taken up by the body’s reticuloendothelial system 
(RES) due to their hydrophobic surface [59]. Zhang et al. has reported PEG 
modified superparamagnetic iron oxide nanoparticles that have a good 
biocompatibility and relatively long circulation time [60]. They have shown that 
the amount of PEG-modified nanoparticles phagocytosed into mouse 
macrophage cells was much lower than that of unmodified nanoparticles. Fine 
ferromagnetic particles coated with poly (ethylene glycol) terminated with amino 
or carboxyl groups have been fabricated to further be functionalized via the 
covalent attachment of proteins, glycoproteins, and other ligands [61]. Because 
these particles are sufficiently small, they are able to reach the site of action, 
prior to systemic clearance. Freeman and Geer have reported that iron particles 
could pass through capillaries when properly conditioned [62, 63]. Ferromagnetic 
particles have also been used for various in vivo applications such as a tracer of 
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the blood flow. Zimmermann et al. proposed the application of erythrocytes or 
lymphocytes containing fine ferromagnetic particles to a desired site by an 
external magnetic field [61]. Interest also recently focused on core-shell 
magnetite particles with a shell of poly(lactide-co-glycolide). 
 
1.5.2. Magnetic resonance imaging 
MRI is a medical imaging method used to obtain images of the body in thin slices 
[64]. When a strong external magnetic field is applied to the body, a hydrogen 
nucleus in water aligns itself in the applied field direction. MRI then measures the 
characteristics of hydrogen nuclei of water after a radio wave is applied to push 
some of these protons out of alignment. Since protons in different tissues of the 
body (fat, muscle, etc.) re-align at different speeds, the different structures of the 
body can be revealed [65].  MRI gives spatial distribution of the intensity of water 
proton signals in the volume of the body. The signal intensity in MRI depends on 
the amount of water in the given place and on the magnetic relaxation times T1 
(longitudinal relaxation time) and T2 (transverse relaxation time).  
 The net magnetization vector is made up of a longitudinal magnetization 
vector and a transverse magnetization vector.  The longitudinal relaxation time 
(T1) is the time required for the z-component of the magnetization vector to return 
to its thermal equilibrium state and the transverse relaxation time (T2) is the time 
required for the component of magnetization vector perpendicular to the 
magnetic field to return to its thermal equilibrium state. Reducing these factors in 
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each case is the ultimate goal in most MRI studies. Improving the final results 
from MRI is only possible when the factors that have the most effect on the MRI 
signal intensity are altered. These factors are the amount of water in a given 
place and the magnetic relaxation times, T1 and T2. Since it is hard to influence 
the water intensity in specific tissue in the body, the most effective way to 
improve the signal intensity is through the alteration of the magnetic relaxation 
times T1 and T2 of the protons in tissue-contained water.  
 Application of contrast enhancers are known to change tissue 
characteristics and hence the MRI scan results [66]. Longitudinal relaxation time 
T1 and transverse relaxation time T2 show remarkably different behavior in the 
presence of paramagnetic species. The resulting effects seen in NMR 
spectroscopy have proven the shortening of both T1 and T2 in the presence of 
paramagnetic species used as contrast agents. Shortening of T1 leads to an  
increase in signal intensity, and shortening of T2 produces broader lines with 
decreased intensity [67]. The net result is a nonlinear relationship between the 
concentration of the contrast agent and the signal intensity. At low concentration 
before reaching the optimal concentration, an increase in contrast agent provides 
an increase in signal intensity due to the effect on T1. Further increase in 
concentration reduces the signal because of the effect on T2. This dictates the 
use of contrast agents with a relatively greater effect on T1 than on T2. 
  Materials with unpaired electrons, so-called “paramagnetic” species, are 
known to have significant effect on T1 and T2 relaxation time. This effect strongly 
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depends on the number of unpaired electrons in these species. Investigations 
have focused on the development of stable paramagnetic metal ion complexes 
using a metal chelating agent. In most cases both the metal ion and the chelating 
agent exhibit substantial toxicity in the unbound state. However, they usually 
create a less toxic, thermodynamically and kinetically stable compound when 
they are bound. Studies have also shown that complexation  of the  metal  ion  
with  organic  ligand,  might  alter paramagnetic  properties  of the metal while 
significantly decreasing the toxicity effect. Gadolinium-DTPA complex is an FDA 
approved contrast agent for use in disease diagnostics. This complex is usually 
eliminated through the kidney. Recently, there have been concerns about the 
toxicity of this material in persons with impaired kidney function. Another, 
relatively new type of paramagnetic contrast agent is superparamagnetic iron 
oxide (SPIO) based colloids. They consist of non-stoichiometric microcrystalline 
magnetite nanoparticles mostly stabilized through polymer coatings. These 
colloids are currently being used as tissue specific contrast agents and studies 
on improvement of these contrast agents are a well-established area of 
pharmaceutical research. The two most widely used contrast agents for MRI 
scanning are gadolinium-based agents, which are T1 contrast agents that cause 
positive contrast enhancement and provide brighter images upon accumulation in 
the target site, and superparamagnetic iron oxide particles, which are T2 contrast 
agents that give negative contrast enhancement and thus darker images in areas 
of accumulation. 
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1.5.3.1. Gd (III) based contrast agents 
 
The significant feature of Gadolinium (III) is the high number of unpaired 
electrons, seven. Even after binding to an organic ligand, The Gd3+ ion retains a 
number of unpaired spins. The free Gd3+ ion is extremely toxic, but there are a 
number of its complexes that are very stable and thus exhibit much less toxicity. 
Slow clearance from the body seems to be a problem that can significantly 
increase the toxicity of any Gd3+ complex. Covalently coupling the ligand to a 
protein to generate tissue-specific contrast agents is considered a potential 
improvement of Gd-based contrast agents. Gd-based contrast agent complexes 
may not be the best choice as of today because of their recently reported toxicity 
effect, but it is a relatively well-known choice, widely  used in  many  MRI  
facilities  on  a  daily  basis [68].   
 
1.5.3.2. Superparamagnetic iron oxide-based contrast agents 
Superparamagnetic iron oxide nanoparticles are known to have a much larger 
effect on relaxation time compared with paramagnetic materials. Because of their 
single domain structure, the entire moments within the crystal structure align in 
the direction of the magnetic field when placed in an external field and enhance 
the magnetic flux. These particles do not retain any magnetization after the 
removal of the external field. This ability to disturb the local magnetic field 
through large magnetic moments leads to a rapid change in coherence of 
surrounding protons called dephasing, hence resulting in a detectable change in 
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the MR signal through altering longitudinal and transverse relaxation of the 
surrounding water nuclei. This implies that the imaging capability provided is not 
from the superparamagnetic iron oxide particles themselves but through their 
influence on T1 and T2 of water. Although the superparamagnetic nanoparticles 
are well known for generating a good MR contrast because of their ability to 
significantly reduce the transverse relaxation T2 time, it has also been 
demonstrated that these particles can generate sufficient T1 contrast for 
biomedical applications as well [69, 70].  
 Stabilized superparamagnetic iron oxide nanoparticles are promising 
contrast agents since their properties can be further modified for the specific 
application. They are relatively non-toxic and rapidly cleared from the organism.  
After the external magnetic field is removed, Brownian motion is sufficient to 
randomize the superparamagnetic nanoparticle orientation, thus leaving no 
magnetization.  
 Superparamagnetic iron oxide nanoparticles are finding applications in 
biomedical research. For example, Zhao et al. has used magnetic nanoparticles 
to detect apoptosis [71]. Apoptosis is an active process of cellular self-destruction 
that plays an important role in number of disorders including neurodegenerative 
diseases [72]. Superparamagnetic iron oxide nanoparticles are currently being 
used as a clinical contrast agent for MRI under the names of Lumirem, 
Gastromark, Ferumoxsil, Abdoscan, Feridex, Endorem and Ferumoxide. Table 2 
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shows some of magnetic nanoparticles that have served as MRI contrast 
enhancing agents in past two decades. 
Table 2. Reported nanoparticle-based MRI contrast agents. 
 
Name                          Size (nm)                    Coating material           References 
 
 
AMI-25 (Feridex;         80-150                         Dextran                                [73] 
 Endorem) 
 
SHU 555A (Resovist) Ca. 62                          Carbodextran                       [74] 
 
AMI-227 (Combidex;   20-40                           Dextran                                [75] 
Sinerem) 
 
CLIO; MION                10-30                           Dextran                                [69]          
 
 
 
1.6. Toxicity Consideration 
Studies have shown that iron oxide nanoparticles require a biocompatible sheath 
to prevent agglomeration that may lead to toxicity in biological media [76]. The 
diameter and surface characteristics of the superparamagnetic iron oxide 
nanoparticles play an important role in their clearance rate, cell toxicity and the 
cellular response to these nanoparticles.  In general, nanoparticles with 
diameters above 200 nm are more likely to be taken up by macrophages. On the 
other hand, small particles with diameters less than 10 nm are removed rapidly 
through extravasation and renal clearance [1]. This indicates that the particle size 
between 10-200 nm offers the best chance to stay in circulation for a longer time. 
In order to prevent a toxic interaction of superparamagnetic iron oxide 
nanoparticles and to prolong plasma half-life of these nanoparticles, amphiphilic 
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coatings are introduced to extend their circulation time from minutes to hours, 
thereby increasing the targeting potential of a surface-modified  contrast agent 
[77].  
 To date, studies have shown that the polymer-coated nanoparticles have 
minimal impact on cell viability and function. Gomez-Lopera et al. have fabricated 
magnetic nanoparticles stabilized with a biodegradable poly (DL-lactide) polymer 
coating [63]. The aim of their work was to synthesize colloidal particles that were 
both magnetic field responsive and useful as drug delivery systems. Another 
study shows that dextran-coated superparamagnetic nanoparticles labeled with 
the a cationic peptide had no significant effect on cell viability or the 
biodistribution of human hematopoietic cells [39]. In summary, all studies have 
shown that superparamagnetic iron oxide nanoparticles surface properties can 
influence the uptake of nanoparticles by phagocytic cells. For example, 
carboxydextran-coated superparamagnetic iron oxide nanoparticles appear to be 
internalized by macrophages to a greater extent than dextran-coated 
superparamagnetic iron oxide nanoparticles [78]. The most common reactions 
following the administration of superparamagnetic iron oxide nanoparticles are 
headache, back pain, vasodilatation, and hives [8].  
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Introduction 
Magnetic nanoparticles have been intensively studied for their applications in 
biomedical areas such as enzyme and protein immobilization, targeted drug 
delivery, in vitro cell separation and magnetic resonance (MR) contrast 
enhancement [1-7]. Several investigations have been carried out in the field of  
superparamagnetic iron oxide nanoparticles because of their high magnetic 
susceptibility and  relatively low cytotoxicy [8]. Superparamagnetic nanoparticles 
possess an advantage in that they do not retain any magnetism after removal of 
an external magnetic field [12]. A recurrent problem with these particles, 
however, is that the formation of agglomerates in biological fluids is common. 
These agglomerates are subject to clearance and rapid biodegradation by the 
reticuloendothelial system [13, 14]. Agglomeration may also lead to unwanted 
occusions upon injection.   
 Researchers have been studying different techniques to overcome these 
difficulties by engineering the surface of iron oxide nanoparticles. To enable 
these nanoparticles for biomedical applications, substances that make them 
stable, biodegradable must be implemented colloidally. Also desirable is the 
ability to attach complex biological molecules, such as peptides, hormones, 
vitamins or drugs [16-19]. Finally, magnetic nanoparticles are desired to have a 
hydrophilic surface and size less than 200 nm for biomedical applications. 
 Several methods have been reported for surface modification of 
superparamagnetic iron oxide nanoparticles. Surface protection using a non-
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polymeric organic layer, like oleic acid, or small “monomeric” organic molecules, 
have been developed as a method to stabilize magnetic nanoparticles [48]. 
Several synthetic and natural polymers have also been reported to modify the 
surface of superparamagnetic nanoparticles to enhance their function in vivo. 
These techniques often resulted in the formation of iron oxide nanoparticles with 
a wide particle size distribution and poor crystallinity [34]. Moreover, many of 
these polymer stabilizers lack a functional component to bind to the magnetite 
surface which decreases their long-term dispersion stability.  
 This dissertation reports a novel approach to synthesize iron oxide within 
polyvinylamine (PVAm) nanoparticles. PVAm is a water soluble polymer with a 
relatively high density of reactive amino groups [20]. It  has been utilized as a 
chelating agent for heavy metals due to the presence of primary amine side-
groups along the polymeric backbone [21]. The resulting PVAm nanoparticles 
containing iron oxide were dispersible in water and stable at biological pH (7.4). 
A relatively high density of reactive amino groups on the surface of these 
nanoparticles may enable them to functionalization for targeted imaging or drug 
delivery. 
 
2. Materials and Methods 
2.1. Materials 
N-vinylformamide (NVF; Aldrich) was used as a monomer and 2, 2’-Azobis(2,4-
dimethylpentanitrile) (Vazo-52, purchased from DuPont) used as an initiator for 
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the polymerization reaction of N-vinylformamide. Vazo-52 has 10 hr half life at 52 
°C which makes it a good candidate for reaction polymerization at low 
temparutures.. Deionized water (DI) was obtained from a Barnstead EasyPure 
water purifier. All materials were used as received. 
 
2.2. Synthesis of Non-Degradable Cross-Linker 
NVEE was synthesized following the procedure reported in appendix I. NVEE is 
a NVF derivative, which makes it a good candidate for co-polymerization with 
NVF. 
 
2.3. Synthesis of Poly (N-vinyl Formamide) Nanoparticles 
Cross-linked PNVF nanoparticles were fabricated by inverse microemulsion 
polymerization of NVF with NVEE.  NVF (350 μL) was added to 20 mg of initiator 
and stirred, then 50 mg of NVEE and 165 μL of DI water were added to this 
solution, respectively. The resulting transparent solution was next added to 100 
mL hexane containing 30 mg of initiator, Tween 80 (3 g) and Span 80 (4.1 g) 
under vigorous stirring. In the next step, the microemulsion was transferred into a 
150 mL jacketed three-neck reactor. Before the polymerization reaction started, 
nitrogen was sprayed for 15 minutes to remove oxygen. The polymerization 
reaction was then carried out at 50ºC for 24 hours. PNVF nanoparticles were 
purified by centrifugation at 15,000 rpm for 45 minutes at room temperature. The 
particles then were re-dispersed in DI water and dialyzed against DI water for two 
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days. To optimize the final size of PNVF nanoparticles several experiments were 
performed. Appendix II shows the optimization results. 
  
2.4. Synthesis of Polyvinylamine Nanoparticles 
PVAm nanoparticles were produced by subsequently hydrolyzing the PNVF 
particles (Fig. 4).  
 
Figure 4. Synthesis of cross-linked polyvinylamine nanoparticles. 
 
1M NaOH solution was prepared by dissolving 1.2 g NaOH in 30 mL PNVF 
suspension (~5 mg/mL) and stirred under nitrogen. The resulting solution was 
then incubated at 80°C for 12 hours.  The PVAm nanoparticles obtained from this 
process were purified by dialysis against water for 5 hours. This procedure 
resulted in the production of PVAm nanoparticles. The amount of formamide 
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group converted amine group can be measured using NMR spectra [79]. The 
effect of hydrolysis time on PVAm size and charge was also studied. Hydrolyzed 
nanoparticles contained amine functional groups both inside and at the surface. 
 
2.5. Fabrication of Magnetic Polyvinylamine Nanoparticles 
To synthesize the iron oxide inside the PVAm nanoparticles, the following 
reaction should be performed in aqueous  solution using a molar ratio of  Fe (II) / 
Fe (III) = 0.5 [80] . 
 
4332 2 OFeFeClFeCl →+  
 
FeCl2 (4 g) and FeCl3 (5.2 g) were successively dissolved in 25 mL of 
deoxygenated PVAm nanoparticle suspension (5 mg/mL). This mass ratio was 
determined experimentally to yield roughly a 0.5 ratio within nanoparticles [22]. 
The solution was stirred over night at room temperature. 
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Figure 5. Synthesis of magnetic PVAm nanoparticles. Amine functional groups chelate iron ions 
inside and on the surface of the polymeric matrix. Black dots depict the iron oxide inside the 
polymeric matrix after oxidation. 
 
Next the solution of PVAm nanoparticles containing FeCl2 and FeCl3 was 
transferred to a centrifuge tube and centrifuged for 30 minutes at 15,000 rpm. 
The pellet was re-dispersed in deoxygenized water and the supernatant was 
stored to further study the iron uptake by PVAm nanoparticles. The resulting 
solution was added drop-wise into 50 mL of 1 M NaOH solution under vigorous 
stirring. The last step generated a black-brown precipitate almost instantly. The 
precipitate was isolated using a magnetic field and the supernatant was removed 
from the precipitate by decantation. Deoxygenated water was then added to the 
easily redispersed precipitate and the solution was centrifuged at 15,000 rpm for 
30 minutes. HCl (0.1 M) solution was added to the precipitate under stirring to re-
disperse the magnetic pellet in centrifuge tubes. The resulting opaque solution 
then was washed with PBS with pH > 9 and then with PBS (pH 7.4). 
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2.6. Characterization  
2.6.1. Size, Size Distribution and Charge Characterization of PVAm 
and Magnetic PVAm Nanoparticles  
  
2.6.1.1. Transmission electron microscopy studies 
The size and morphology of magnetic nanoparticles were observed by 
transmission electron microscopy (JEOL 1200 EXII) at 200 Kv. In addition, 
energy dispersive X-ray spectroscopy (EDX) was used to qualify the iron oxide in 
PVAm nanoparticles. The powder was dissolved in water and was drop-cast onto 
a 300 mesh carbon-coated copper grid that was air dried before imaging.  
 
2.6.1.2. Dynamic light scattering studies 
The size, size distribution and the zeta potential of PVAm nanoparticles and 
PVAm nanoparticles containing iron oxide dispersed in PBS (pH=7.4) were 
measured by dynamic light scattering (Brookhaven Zeta-PALS). Samples were 
diluted prior to the measurements. The zeta potential was determined in the 
presence of 0.1 M KCl solution to maintain the ionic strength required for the 
measurement. Polydispersity was determined according to the method of 
cumulants [81]. 
  
2.6.2. Characterization of Magnetic PVAm Nanoparticles 
2.6.2.1. Iron Content Measurement 
2.6.2.1.1. Iron Uptake 
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To determine the molar ratio Fe (II) / Fe (III) inside polymeric nanoparticles, UV 
absorbance spectra were obtained to study the amount of iron ions coordinated 
by PVAm nanoparticles performing the following protocol. Reagent A was made 
by adding 0.25 g ferrozin to 0.401 g ammonium acetate and diluted to 50 mL. 
Hydroxylamine HCL (1.4 mmol/L) in 2 mol/L HCL and 10 mol/L ammonium 
acetate adjusted to pH 9.5 with ammonium hydroxide were used as reagent B 
and C respectively. Standard curve was made using ferrous ammonium sulphate 
and water to make serial dilutions. To find the Fe (II) concentration, UV samples 
were prepared by adding 3 mL H2O to 100 μL of sample, then 100 μL of reagent 
was added to the solution and kept for 10 minutes at room temperature. The 
absorbance then was measured at 562 nm. Next, 1 mL of the above mixture was 
added to 150 μL of reagent B where it was mixed and allowed to stand overnight 
to reduce Fe (III) to Fe (II), then 50 μL of reagent C was added and the solution 
was kept for 10 minutes at room temperature. UV spectra were recorded at the 
same wavelength to measure the concentration of Fe (II). 
 
2.6.2.1.2. Final Iron content 
The content of Fe3O4 in magnetic polymeric particles was measured by atomic 
absorption spectroscopy (AA). The suspension of magnetic PVAm was diluted 
with HCL (2% V/V).  The instrument used was a Perkin Elmer AAnalyst 300 with 
a AS90 plus auto sampler. A regular sensitivity nebulizer without an impact bead 
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was installed as well as a 10 cm single slot burner head.   The bulb was a Perkin 
Elmer Fe bulb. 
 
2.6.2.2. Magnetic measurements  
The magnetization curves of PVAm nanoparticles containing iron oxide were 
carried out at room temperature (magnetic field between -20 and 20 kOe) using a 
Quantum Design MPMS 5 superconducting quantum interface device (SQUID) 
magnetometer. Mass magnetization is defined as the magnetic moment per total 
mass of the sample. 
 
2.6.2.3. Fourier Transform Infrared Spectroscopy Studies 
The Fourier transform infrared (FTIR) spectra of the sample were recorded on a 
MAGNA-IR 560 spectrometer. The freeze-dried samples (2 mg) of pure PVAm (5 
mg/mL) and PVAm containing iron oxide (6.5 mg/mL) were ground with KBr, and 
the mixture was compressed into a pellet. The spectrum was taken from 3999 to 
500 cm-1 (4 cm-1 resolution, 32 scans).  
 
2.6.2.4. In vitro Cytotoxicity Studies 
To test whether the PVAm nanoparticles containing iron oxide have 
biocompatibility, a cytotoxicity assay was performed. A549 cells were trypsinized, 
counted and diluted to a concentration of approximately 80,000 cells/mL. Then 
0.1 mL was added to each well of a 96-well plate and the cells were incubated in 
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5% CO2 incubator at 37°C for 24 hours. Medium were then removed and 
replaced with a mixture of 100 µL fresh culture medium and 20 µL MTS reagent 
solution. The cells were incubated for 3 hours at 37°C in the 5% CO2 incubator. 
The absorbance of each well was then measured at 490 nm to determine cell 
viability. 
 
2.7. Results and Discussion. 
2.7.1. Size and charge characterization of PVAm and magnetic PVAm 
Nanoparticles. 
 
2.7.1.1. Dynamic Light Scattering 
The presence of reactive amine groups along with the hydrophilicity of PNVF and 
PVAm made this polymer an attractive candidate for incorporating iron oxide into 
nanoparticles. Methods were developed to determine reaction conditions that 
provided the desired particle size and size distributions of both PVAm and 
magnetic PVAm nanoparticles. Hydrolysis time showed a significant effect on 
PVAm size and charge. The size of PVAm nanoparticles increased with 
increasing time (Fig. 6A). Zeta potential of PVAm nanoparticles also increased 
over time (Fig. 6B). It is hypothesized that the increased particle charge resulted 
in an increase in osmotic pressure due to increased concentration within the 
nanoparticles [82]. 
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Figure 6. PVAm (A) size and (B) charge increases with hydrolysis time during the conversion of 
PNVF to PVAm. 
 
In general, in polyelectrolyte gels there is a difference in mobile ion 
concentrations inside and outside the gel. This difference is caused by the 
requirement to satisfy electroneutrality and leads to an osmotic pressure 
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difference between the gel and the equilibrium solution. Table 3 shows the size 
and zeta potential of nanoparticles that were used to fabricate magnetic PVAm 
nanoparticles. The PNVF nanoparticles were hydrolyzed for 20 minutes to obtain 
particles with the specified size and charge. 
  
Table 3. Characteristics of synthesized nanoparticles. 
 
                           Nanoparticle Diameter (nm)    Polydispersity   Zeta Potential (mV)     
 
PNVF   112 ± 13         0.182 ± 0.089           -5.6 ± 0.3                 
 
PVAm   186 ± 3                           0.159 ± 0.002            23.9 ± 2.6 
 
Magnetic PVAm 155 ± 5         0.146 ± 0.003         15.5 ± 0.1 
 
 
 
Magnetic nanoparticle size and size distributions were also studied. Dynamic 
light scattering studies further confirmed that PVAm and magnetic PVAm 
nanoparticles had low polydispersity. In most cases, particles with a 
polydispersity < 0.2 are considered narrowly dispersed (Table 3).  
 
2.7.1.2. Transmission Electron Microscopy 
Transmission electron microscopy (TEM) was used to probe PNVF, PVAm and 
magnetic PVAm nanoparticle morphology. Images from TEM indicated that 
PNVF (Fig. 7A), PVAm (Fig. 7B) and magnetic PVAm nanoparticles (Fig. 7C & 
7D) were spherical with a ruffled surface. The ruffled surface morphology was 
expected since nanoparticles must be imaged in a dry state when using TEM. 
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Figure 7. TEM analysis showed that (A) PNVF, (B) PVAm, and (C & D) magnetic PVAm 
nanoparticles were spherical. In addition, small iron oxide nanoparticles (<10 nm) were evident 
within magnetic PVAm nanoparticles. 
 
TEM was also used to detect the iron oxide inside nanoparticles (Fig. 7C & 7D). 
The dark spots inside the nanoparticles along with the energy dispersive X-ray 
spectroscopy (EDX) data of the same magnetic particles (Fig. 8) indicated the 
presence of small iron oxide nanoparticles (<10 nm) inside the PVAm 
nanoparticles. Characteristics X-Rays results from non-radiative transition of 
electron between shells within a, K, L or M family of an atom. K lines are the 
most energetic lines consisting of Kα1, Kα2, Kβ1, and Kβ2 radiations. Other 
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researchers have reported similar morphology of magnetic nanoparticles [83, 84].  
Image analysis software determined that dried PVAm and magnetic PVAm 
nanoparticles were roughly 100 nm.  
 
 
Figure 8. EDX of magnetic PVAm nanoparticles revealed two iron peaks that indicated the 
presence of iron inside the nanoparticles. 
 
 Comparing with the reported method for preparing stable iron oxide 
nanoparticles, the synthetic procedure reported here was simple since 
stabilization was accomplished during the iron oxide synthesis and the final 
product did not require any further size-selection process. Zaitsev et al. have 
reported the in situ preparation of magnetic nanoparticles by addition of a 
magnetite nanoparticle dispersion to the seed precipitation polymerization of 
methacrylic acid and hydroxyethyl methacrylate monomers [85]. The magnetite 
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and the polymer coated magnetite nanoparticles were reported to be ~6 - 80 nm 
and 340 - 400 nm in diameter, respectively. In another study, Arias et al. have 
reported polymer coated particles ~144 nm in diameter with ~84 nm magnetic 
cores [86]. The stabilized magnetic PVAm nanoparticles reported here are larger 
than polymer stabilized iron oxide systems previously reported. The iron oxide 
nanoparticles formed within PVAm nanoparticles, however, were <10 nm in 
diameter. Iron oxide particles formed in the presence of dextran and polyvinyl 
alcohol were similar in size; 4.11 ± 0.85 nm and 5.78 ± 1.30 nm, respectively 
[87].   
 
2.7.2. Characterization of magnetic PVAm Nanoparticles. 
2.7.2.1. Quantification of Iron Oxide Fabricated in Polyvinylamine 
Nanoparticles (UV) 
 
A UV study was used to quantify the uptake of iron ions by PVAm nanoparticles 
(Table 4). To maintain the stochiometric molar ratio of Fe (II) / Fe (III) inside the 
particle, two different molar ratios of iron chloride II and III were added to the 
PVAm nanoparticle suspension. The amount of free iron ions was then found 
using UV analysis. Results indicated that the uptake of Fe (II) at low 
concentration (0.08 g/mL) is 47% lower than its uptake at higher concentration 
(0.16 g/mL). It is hypothesized that the larger electrostatic/ionic interaction 
between Fe (III) and amine groups relative to Fe (II) could be a reason for the 
higher uptake of Fe (III) ions by PVAm at low concentrations. One should 
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consider the concentration of amine groups inside PVAm nanoparticle, which 
may have a significant affect on the uptake of iron ions. 
Table 4. Iron uptake by PVAm nanoparticles. 
Fe(II)/Fe(III) 
added to 
PVAm solution 
Fe(II)/Fe(III) 
inside 
particle 
%Fe(II) 
uptake by 
particle 
%Fe(III) 
uptake by 
particle 
%Total 
uptake 
of iron 
% Iron 
oxide after 
purification 
(AA) 
0.50 0.15 37 93 77 10 ± 0.13 
1 0.43 55 96 78 12 ± 0.01 
 
 
2.7.2.1. Quantification of Iron Oxide Fabricated in Polyvinylamine 
Nanoparticles (AA) 
 
Atomic absorption spectroscopy (AA) of purified magnetic nanoparticles 
demonstrated that the magnetite concentration in PVAm particles was ~12% 
(wt/wt). Data from the UV study using an indirect quantification method 
suggested that the total magnetite concentration inside polymer particles was of 
78% (wt/wt), which was significantly higher than the 12% wt/wt detected using 
AA. This means that some iron ions were lost during washing or iron oxide 
nanoparticles formed during oxidation have been removed during purification. 
Gupta et al. have reported the total of particles presented in one gram of PEG 
modified iron oxide nanoparticles to be 1.71×1017 [1]. A total of 1.073×1022 iron 
particles were present in one gram of PVAm nanoparticles containing iron oxide 
which is higher than the amount reported for PEG-modified iron oxide 
nanoparticles.  
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Figure 9. Magnetic PVAm nanoparticles isolated under a magnetic field. 
 
The synthesized PVAm superparamagnetic nanoparticles were well dispersed in 
water and showed magnetic properties upon applying a magnetic field (Fig. 9). 
Particles concentrated by the magnetic field were readily redispersible. These 
results suggested that the magnetic PVAm nanoparticles offer colloidal stability 
without agglomeration. 
 
2.7.2.2. Magnetization Results 
The relative magnetization curves were determined as a function of magnetic 
field strength for magnetic PVAm nanoparticles (Fig. 10A). The magnetic PVAm 
nanoparticles were characterized by a high magnetic moment in a high magnetic 
field (generally, about 5 to 90 emu/g of metal oxide). The magnetic moment in 
the absence of an applied field was subtracted from the result. The 
magnetization curve exhibits zero magnetization upon the removal of magnetic 
field, which is a characteristic behavior of superparamagnetic particles. This 
Time = 0 min Time = 40 minTime = 25 minTime = 15 min Time = 60 min
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indicates that the iron oxide incorporated in nanoparticles corresponds to the 
single-crystal domain, exhibiting only one orientation of magnetic moment.  
 
Figure 10. (A) Magnetization vs. applied magnetic filed for ~150 nm and (B) ~ 500 nm magnetic 
PVAm nanoparticles at room temperature. 
B: 
A: 
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The saturation magnetization of the ≈150 nm magnetic PVAm nanoparticles was 
30 emu/g. In addition, Selim et al. have reported saturation magnetization of 
lactobionic acid (LA) modified iron oxide to be about 20 emu/g [88]. Their result 
proved that LA modified nanoparticles with saturation magnetization about 20 
emu/g offered potential to be used as MRI contrast agents. The high 
magnetization of magnetic PVAm nanoparticles makes them susceptible to the 
magnetic field and, therefore, they are a candidate for MRI contrast 
enhancement as well. The mass magnetization of particles depended on the size 
of the particle providing credence to literature [15]. These results showed that 
larger magnetic PVAm nanoparticles had greater mass magnetization (Fig. 10B). 
Experimental values for the saturation magnetization of magnetic nanoparticles 
reported for similarly sized iron oxide nanoparticles ranges from 30-60 emu/g, 
where the bulk magnetite saturation can be as high as is 92 emu/g [89]. The 
reported values for magnetic PVAm nanoparticles were lower suggesting that the 
amount of iron oxide incorporated inside PVAm nanoparticles is relatively low. To 
achieve higher saturation magnetization it may be necessary to increase the 
amount of iron oxide inside PVAm nanoparticles. 
 
 
2.7.2.3. The Coordination of PVAm and Iron Oxide on the Preparation of 
Magnetic PVAm Nanoparticles 
 
FTIE spectra were recorded to study the coordination of iron within PVAm 
nanoparticles .FTIR spectra of pure PVAm and magnetic PVAm nanoparticles 
showed that N-H absorption bands were shifted from 3271.14 to 3178.82 cm-1 in 
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the presence of iron oxide (Fig. 11). The stretching of this amine suggested that 
iron oxide interacted with amine groups of PVAm. The interaction between amine 
groups and iron molecules is expected since primary amines are known to be 
chelating agents for metals like iron [21] . 
 
Figure 11. FTIR spectra of PVAm and magnetic PVAm nanoparticles. 
 
2.7.2.4. Cytotoxicity Analysis 
A cell proliferation assay was performed using human umbilical cord vascular 
endothelial cells (HUVEC) to test cell viability in the presence of PVAm and 
magnetic PVAm nanoparticles. The viability of the cells was determined after 24 
hours. Results showed that magnetic PVAm nanoparticles have an IC50 > 2 
mg/mL (Fig. 12). Gupta et al. has reported that PEG-coated nanoparticles 
showed no cytotoxic effects to cells and they remained more than 100% viable 
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relative to non-modified iron oxide nanoparticles at concentration as high as 1 
mg/mL [1]. The toxic behavior of PVAm nanoparticles (IC50 ≈ 0.1 mg/mL) is likely 
related to its high positive charge [90]. The increased cell viability in magnetic 
PVAm nanoparticles may be explained by the fact that primary amine groups in 
PVAm nanoparticles were occupied through association with iron ions. This 
interaction also decreased the zeta potential of nanoparticles from 23.9 mV to 
15.5 mV.  
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Figure10. PVAm and magnetic PVAm nanoparticles Cytotoxicity 
 
2.8. Conclusion 
In this study, magnetic PVAm nanoparticles about 150 nm in size with a very 
narrow size distribution have been reported. The chelating property of primary 
 50 
amine functional groups in PVAm nanoparticles was suspected to hold iron ions 
inside the polymeric network. An oxidation reaction was then carried out inside 
PVAm nanoparticles to fabricate superparamagnetic iron oxide nanoparticles in 
situ. Magnetic PVAm nanoparticles were easily isolated via application of an 
external magnetic field and demonstrated excellent magnetic stability. Magnetic 
PVAm nanoparticles did not retain any magnetization upon after the removal of 
an external magnetic field which proved the superparamagnetic characteristic of 
these nanoparticles. The relatively low cytotoxicity of magnetic PVAm 
nanoparticles makes them a good candidate for biomedical applications. In 
addition, these nanoparticles possess reactive primary amines that may be 
modified to enable targeted delivery of this contrast enhancing agent. 
 
2.9. Future Work 
Research related to magnetic PVAm nanoparticles is of course far from closed 
with this thesis. Future work will aim to improve the size and charge of PVAm 
and magnetic PVAm nanoparticles. Future efforts can address improving the 
magnetization of magnetic PVAm while maintaining the size of these 
nanoparticles. 
 Next, magnetic PVAm nanoparticles will be modified to enable targeted 
delivery. Unbound amine groups of magnetic PVAm nanoparticles will be 
conjugated with ICAM-1 peptides to study their function in vivo. ICAM-1 peptides 
associate with receptors of the integrin family, thereby mediating cell-cell 
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interactions and allowing for signal transduction.  These modified nanoparticles 
will later be used as MRI contrast enhancers for molecular imaging. 
 Polyvinyl alcohol will be synthesized as an alternative to PVAm 
nanoparticles. Polyvinyl alcohol is a water-soluble synthetic polymer. It is usually 
prepared through the removal of acetate groups of polyvinyl acetate via partial or 
complete hydrolysis. The polyvinyl alcohol nanoparticles can then be used to 
incorporate iodine. Iodine is known as a substance that enhances the contrast in 
X-Ray computer tomography (CT) scanning.  
 Later, the contrast enhancing property of the modified magnetic PVAm 
nanoparticles in MR imaging will be compared with the same property of 
polyvinyl alcohol containing iodine in X-Ray computer tomography (CT) 
scanning.  
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4. Appendix 
Appendix I 
2.2. Synthesis of Non-Degradable Cross-Linker 
 
 To synthesize 2-(N-vinylformamido)ethyl ether NVEE (cross-linker) a 
mixture of N-vinylformamide (21 g), potassium t-butoxide (35.44 g) and 
dicyclohexyl-18-crown-6 (3 g) in anhydrous THF was stirred vigorously at room 
temperature for 45 minutes to activate secondary amine group and then cooled 
in an ice bath. Bis(2-bromthyl)ether (27.8 g) was added drop wise, and the 
mixture was stirred at room temperature for 72 hours. In the next step, potassium 
bromide salt was removed by filtration and then the reaction mixture was 
concentrated under vacuum and diluted with 300 mL of water. The crude product 
was obtained by extraction with chloroform five times (50 mL× 3). The combined 
organic layers were washed twice with brine and dried over anhydrous sodium 
sulfate. The resulting product was recovered after concentration in a vacuum 
distillation column and purification by chromatography on silica (ethyl 
acetate/hexane: 8:2 v/v). 
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Appendix II 
Monomer (μL)   Crosslinker (μL)    Surfactant (gr)      water (μL)    PNVF hydrodynamic size (nm) 
 
 
      350               50                       7.1                165                   112 
 
      350               50                       14.2              165                   259 
 
      350               50                       21.3              165                   141 
 
      350               50                       28.4              165                   279 
 
      350               50                       21.3               42.5                 182 
 
      350               50                       21.3                20                    251 
 
      166.5            33.5                    21.3                165                  209 
 
      150               50                       21.3                165                  216 
